Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Sugiura T, Uesaka K, Kanemoto H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):977–85.
2. Narimatsu H, Iwasaki H, Nakayama F, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res. 1998;58(3):512–8.
3. Watkins WM. Biochemistry and genetics of the ABO, Lewis, and P blood group systems. Adv Hum Genet. 1980;10:1–136, 379–185.
4. Kawa S, Tokoo M, Oguchi H, et al. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose. Pancreas. 1994;9(6):692–7.
5. Shimizu Y, Sugiura T, Ashida R, et al. Prognostic role of preoperative duke pancreatic monoclonal antigen type 2 levels in patients with pancreatic cancer. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13564-7.